Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Enlicitide/Rosuvastatin FDC vs Coadministered Single Entities in Healthy Adults
NCT07300280Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1 trial of enlicitide in hypercholesterolemia (4 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity, Area Under the Concentration-Time Curve from Time 0 to Last and 1 more. Started Dec 2025; status: active, not recruiting.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07300280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300280.